Prospective, multicentre, international Registry of male and female patients newly diagnosed with Atrial Fibrillation and treated with Rivaroxaban

Trial Profile

Prospective, multicentre, international Registry of male and female patients newly diagnosed with Atrial Fibrillation and treated with Rivaroxaban

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 26 Jul 2016

At a glance

  • Drugs Rivaroxaban (Primary)
  • Indications Atrial fibrillation
  • Focus Therapeutic Use
  • Acronyms RIVER
  • Sponsors Bayer
  • Most Recent Events

    • 10 Mar 2016 Accrual to date is 645% according to the United Kingdom Clinical Research Network record.
    • 13 Dec 2015 Accrual to date is 205% according to the United Kingdom Clinical Research Network record.
    • 15 Nov 2015 Accrual to date is 60% according to the United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top